Autonomix Medical, Inc. 10-K/A — AI Bull & Bear Analysis

The amended 10-K filing for Autonomix Medical serves as a critical update on the company's governance and financial standing. While the company has successfully updated its executive suite and aligned incentives with clinical success, the underlying financial metrics reveal a business struggling with a massive cash burn and a lack of revenue. The tension between a high-pedigree leadership team and a fragile balance sheet defines the current investment thesis. Investors are left to weigh the potential of a binary clinical catalyst against the very real risk of insolvency. The company's ability to secure additional funding and remediate its internal control deficiencies will be the primary determinants of whether it can survive long enough to realize the value of its AI-driven cardiac technology. The filing underscores a company at a crossroads, where professional management is fighting against a ticking clock of financial depletion.